Retatrutide · research summary

Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.

Diabetes, metabolic syndrome and obesity : targets and therapy · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Scoping review
“The present scoping review aimed to synthesize recent evidence on the effectiveness and safety of anti-obesity medications (AOMs).”

Subjects

Individuals with overweight or obesity
“A structured literature search was conducted in PubMed and Scopus in May 2025 to identify original studies published within the previous five years involving individuals with overweight or obesity receiving pharmacological interventions.”

Sample size

42 articles representing 41 unique studies
“A total of 42 articles representing 41 unique studies, predominantly randomized controlled trials (RCTs), were included in the evidence synthesis.”

Duration

Treatment durations of 20–70 weeks
“while tirzepatide produced approximately 15–21% weight reduction over treatment durations of 20–70 weeks.”

Reported findings

GLP-1 RA consistently demonstrated substantial weight-loss efficacy, with semaglutide achieving approximately 10–16% weight loss
“Among these, GLP-1 RA consistently demonstrated substantial weight-loss efficacy, with semaglutide achieving approximately 10–16% weight loss, while tirzepatide produced approximately 15–21% weight reduction over treatment durations of 20–70 weeks.”
Tirzepatide produced approximately 15–21% weight reduction
“while tirzepatide produced approximately 15–21% weight reduction over treatment durations of 20–70 weeks.”
Gastrointestinal adverse events were the most frequently reported across incretin-based therapies
“Gastrointestinal adverse events (AEs) were the most frequently reported across incretin-based therapies.”

Source: PubMed 42812898 · DOI 10.2147/DMSO.S626279 · all study summaries

Reported findings

GLP-1 RA consistently demonstrated substantial weight-loss efficacy, with semaglutide achieving approximately 10–16% weight loss

“Among these, GLP-1 RA consistently demonstrated substantial weight-loss efficacy, with semaglutide achieving approximately 10–16% weight loss, while tirzepatide produced approximately 15–21% weight reduction over treatment durations of 20–70 weeks.”

Tirzepatide produced approximately 15–21% weight reduction

“while tirzepatide produced approximately 15–21% weight reduction over treatment durations of 20–70 weeks.”

Gastrointestinal adverse events were the most frequently reported across incretin-based therapies

“Gastrointestinal adverse events (AEs) were the most frequently reported across incretin-based therapies.”